AHG (Akso Health Group) Research & Development: $0.00 Mil (TTM As of Sep. 2025)


AHG Akso Health Group AHG
36 GF Score
Price $1.52
GF Value $0.47
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Akso Health Group Research & Development?

Akso Health Group AHG +10.14% 36 Research & Development is $0.00 Mil as of Sep. 2025. GuruFocus rates AHG with a GF Score™ of 36/100 and a GF Value™ of $0.47 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Akso Health Group's Research & Development for the six months ended in Sep. 2025 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was $0.00 Mil.

Akso Health Group  (NAS:AHG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Akso Health Group Research & Development Related Terms

Akso Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for Akso Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akso Health Group Research & Development Chart

Akso Health Group Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.42 0.00 0.00 0.00

Akso Health Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
AHG
36GF Score
Akso Health Group AHG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akso Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Akso Health Group (AHG) has a Research & Development of $0.00 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Akso Health Group and its competitors.
Is Akso Health Group's Research & Development too high?
Akso Health Group's current Research & Development is $0.00 Mil. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's Research & Development compare to ACH and EDAP?
Akso Health Group's Research & Development of $0.00 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Akso Health Group and its competitors. Akso Health Group's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.47, compared to a current price of $1.52 — trading 223.4% above its estimated fair value. The current Research & Development is $0.00 Mil. Akso Health Group's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Akso Health Group (AHG), the current Research & Development is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akso Health Group (AHG) Overvalued in 2026?

Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued. The current stock price of $1.52 is trading 223.4% above its estimated GF Value™ of $0.47. GuruFocus considers Akso Health Group to be Significantly Overvalued.

Key valuation signals for AHG:

  • Research & Development: $0.00 Mil
  • GF Value™: $0.47 vs. price of $1.52 (223.4% above fair value)
  • GF Score™: 36/100 with 2 warning signs

No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akso Health Group Business Description

Address No. 44, Moscow Road, Qianwan Bonded Port Area, Room 8201-4-4(A), 2nd Floor, Qiantongyuan Building, Qingdao Pilot Free Trade Zone, Shandong, CHN
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score

Get the complete analysis for AHG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price
$0.47
GF Value